US pharma tariffs take effect; select Indian drugs win exemption

The United States commenced enforcement of its comprehensive 100% pharmaceutical tariff on designated products today, marking a significant shift in cross-border drug trade. However, the tariff's scope has been narrowed through targeted exemptions that will benefit Indian pharmaceutical manufacturers producing specific specialty drugs.

India has secured zero-duty status for select pharmaceutical products alongside 19 other jurisdictions under the new US trade policy. The exemptions apply specifically to speciality drugs meeting particular criteria, reflecting Washington's approach to maintaining access to certain medications while pursuing broader tariff objectives. The precise list of qualifying products and the duration of these exemptions remain key details for Indian pharma exporters.

Generic medications, which form the backbone of India's pharmaceutical export portfolio to the United States, continue to fall outside the relief framework. This distinction underscores the tariff's differential impact across the Indian pharma sector. Generic drugs represent a substantial portion of US pharmaceutical imports from India, making their exclusion a significant concern for manufacturers who depend on the American market.

The tariff implementation comes amid broader trade policy adjustments affecting multiple sectors. Indian pharmaceutical companies now face a bifurcated landscape: potential tariff burdens on generic products offset partially by relief provisions for specialty medications. Industry observers will closely monitor how the exemptions influence trade flows and whether additional products may qualify for duty-free status in subsequent policy reviews.